STEMXCELL Trademark

Trademark Overview


On Wednesday, June 2, 2021, a trademark application was filed for STEMXCELL with the United States Patent and Trademark Office. The USPTO has given the STEMXCELL trademark a serial number of 90750083. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Wednesday, March 1, 2023. This trademark is owned by PrimeGen US, Inc.. The STEMXCELL trademark is filed in the Pharmaceutical Products category with the following description:

Stem cells for medical or veterinary use; activated mesenchymal stem cells for medical or veterinary use; non-activated mesenchymal stem cells for medical or veterinary use; therapeutic pharmaceuticals comprised of stem cells for the treatment of liver disease, kidney disease, heart disease, wound healing and osteoarthritis, and for the treatment of immune system related diseases and disorders; injectable pharmaceuticals comprised of stem cells for the treatment of liver disease, kidney disease, heart disease, wound healing and osteoarthritis, and for the treatment of immune system related diseases and disorders; cytokines produced by stem cells, including in culture media, for use as injectables for medical or veterinary use; stem cells combined with other added cytokines, inhibitors, or small molecules for use as injectables for medical or veterinary use
stemxcell

General Information


Serial Number90750083
Word MarkSTEMXCELL
Filing DateWednesday, June 2, 2021
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateWednesday, March 1, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesStem cells for medical or veterinary use; activated mesenchymal stem cells for medical or veterinary use; non-activated mesenchymal stem cells for medical or veterinary use; therapeutic pharmaceuticals comprised of stem cells for the treatment of liver disease, kidney disease, heart disease, wound healing and osteoarthritis, and for the treatment of immune system related diseases and disorders; injectable pharmaceuticals comprised of stem cells for the treatment of liver disease, kidney disease, heart disease, wound healing and osteoarthritis, and for the treatment of immune system related diseases and disorders; cytokines produced by stem cells, including in culture media, for use as injectables for medical or veterinary use; stem cells combined with other added cytokines, inhibitors, or small molecules for use as injectables for medical or veterinary use

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, August 25, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NamePrimeGen US, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSanta Ana, CA 92705

Trademark Events


Event DateEvent Description
Wednesday, March 1, 2023ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Wednesday, March 1, 2023ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Wednesday, March 1, 2023ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Monday, August 15, 2022NOTIFICATION OF FINAL REFUSAL EMAILED
Monday, August 15, 2022FINAL REFUSAL E-MAILED
Monday, August 15, 2022FINAL REFUSAL WRITTEN
Tuesday, July 19, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, July 18, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, July 18, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, February 23, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, February 23, 2022NON-FINAL ACTION E-MAILED
Wednesday, February 23, 2022NON-FINAL ACTION WRITTEN
Wednesday, February 16, 2022ASSIGNED TO EXAMINER
Wednesday, August 25, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, June 5, 2021NEW APPLICATION ENTERED